NattoPharma (NATTO)

[Alex]

Det ble den posten spist ja. Tror jaggu det kan være duket for oppgang her.

Jeg står nok for halve volumet, skulle ha en lyttepost. Umulig å få noe volum uten å gå litt opp.

[Christian]

Jeg tenker du har gjort et godt kjøp her, de har jo faktisk levert rundt guidingen den siste tiden. Jeg er veldig spent på hva de klarer å levere i 2019, men det ser jo veldig lovende ut. I motsetning til PHO, så er jo veksten svært kraftig.

[Baardko]

Spørs om det var så lurt å midlertidig selge deler av posten før jul, solgte nesten 80% da og tenkte å kjøpe meg inn igjen senere. Etter oppgang i Funcom, sånn går det når man er utålmodig

[Christian]

Funcom har jo gått opp ca like som Natto fra rundt jul da

[Baardko]

Joda, men skal jeg kjøpe tilbake her nå flytter jeg jo fort kursen noen kroner nordover!

[holmes]

Pleier å fylles på med selgere etterhvert da Men liker utviklingen her for min egen del.

[holmes]

Fin start på uka dette, 12 spenn sluttkurs

[Christian]

Da er jeg faktisk i pluss her.

[vandregutten]

Må i 1000,- for at gå i pluss…

[TekBot]

26/02-2019 09:47:39: (NATTO.OAX) Vitamin K2 vs Vitamin K1 paper published in International Journal of Molecular Sciences

New review paper, completed as part of INTRICARE and EVOluTION research grants,
advances argument for Vitamin K2-specific RDI to benefit more consumers.
Oslo, Norway and Edison, NJ (26 FEB 2019) - The International Journal of
…

Vis børsmeldingen

Molecular Sciences has published a new review paper examining the differences
between vitamins K1 and K2, showing that based on its very molecular structure
K2 is available beyond the liver to support systems like the bone and
vasculature through proper calcium utilization. The review paper, the result of
the INTRICARE and EVOluTION grants awarded to NattoPharma’s International
Research Network by the European Union within the Horizon 2020 Marie Sklodowska
-Curie research and innovation program, is an important step in establishing the
need for a Vitamin K2-specific recommended daily intake (RDI).

The paper is significant because it is a necessary step towards recognizing the
importance of a vitamin K2-specific RDI, an endeavor NattoPharma is currently
spearheading with the help of its research partners, according to NattoPharma
Chief Medical Officer Dr. Hogne Vik.

“This review paper continues to explore the differences between Vitamin K1 with
its known benefit for coagulation and the newly recognized benefits of Vitamin
K2 also to function extrahepatically to support bone and cardiovascular health,”
says Vik. "Practically, the body of evidence today supports a dominant role for
Vitamin K2 in the inhibition of calcification of soft tissues because of its
better bioavailability and bioactivity. Observational studies and gold standard
double-blind, placebo-controlled trials show that Vitamin K2 may inhibit
vascular calcification and even hold progression of vascular stiffness.

“Recognition of Vitamin K2’s benefits as strong and significant elucidated
inhibitor of vascular and soft tissue calcification is one of the core reasons a
separate RDI should be established,” Vik adds. “We are proud that our
partnership with Maastricht University and these prestigious grants have given
us an opportunity to further the understanding of the necessity of obtaining
adequate vitamin K2 for human health.”

Expanding global understanding for the need for additional Vitamin K2 in a diet
to overcome insufficient intake and address significant health concerns will
certainly increase the number of consumers that MenaQ7 can significantly
benefit.

According to the authors, the paper “Vitamin K: Double Bonds beyond Coagulation
Insights into Differences between Vitamin K1 and K2 in Health and Disease”, is
the first to highlight differences between isoforms vitamin K1 and K2 by means
of source, function, and extrahepatic activity. Prof. Schurgers states that
functions of K2 are proving to be beneficial with regard to cardiovascular
diseases and bone metabolism, yet there is a growing body of evidence suggesting
vitamin K2 is involved in multiple cellular processes and might have a
protective role in various organs throughout the human body. To that end it is
important to consider an RDI reflective of these additional roles.

“When exploring the non-coagulation, extrahepatic activities of vitamin K, it is
clear that K2 in its various forms is the highlight of such activity. Therefore,
although history and nomenclature have classed K1 and K2 into the same category,
these molecules can have a very different action in the body,” says Prof.
Schurgers, Professor of Biochemistry of Vascular Calcification and Vice Chair of
Biochemistry at the Cardiovascular Research Institute Maastricht (CARIM),
Maastricht University; and senior author and leader of the research project.
“Major health organizations, such as WHO, European Food Safety Authority (EFSA)
and Food and Drug Administration (FDA) have established RDI for vitamin K, which
is solely based on the dose of K1 to retain an appropriate blood clotting
function. Differences between K1 and K2 merit recognition among national and
international regulatory organizations, and remain open to research.”

The review paper is the result of the INTRICARE (grant agreement No 722609) and
EVOluTION (grant agreement No 675111) grants funded by the European Union within
the Horizon 2020 Marie Sklodowska-Curie research and innovation program, awarded
to NattoPharma’s International Research Network to train a total of 26 Early
Stage Researchers (ESRs) focusing on harnessing endogenous mechanisms for health
and the effect of vitamin K to hold or regress microcalcification and subsequent
cardiovascular disease.

Reference:

Halder M, Petsophonsakul P, Akbulut AC, Pavlic A, Bohan F, Anderson E, Maresz K,
Kramann R, Schurgers L. Vitamin K: Double Bonds Beyond Coagulation Insights Into
Differences Between Vitamin K1 and K2 in Health and Disease. Int J Mol Sci.
2019, 20, 896; doi:10.3390/ijms20040896

(Direct link: https://www.mdpi.com/1422-0067/20/4/896/htm)

About NattoPharma and MenaQ7®

NattoPharma ASA, based in Norway, is the supplement industry world leader in
vitamin K2 research and development. NattoPharma is the exclusive international
supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as
menaquinone-7 (MK-7) with guaranteed actives and stability, clinical
substantiation, and international patents granted and pending; and now the new
MenaQ7® Full Spectrum, which delivers menaquinones 6, 7, and 9. The company has
a multi-year research and development program to substantiate and discover the
health benefits of Vitamin K2 for applications in the marketplace for functional
food and dietary supplements, in addition to exclusive access to the research
efforts of its pharmaceutical arm, Kaydence Pharma AS (est. 2017), outside of
the pharmaceutical domain. With a global presence, the company established its
North American subsidiary, NattoPharma USA, Inc., in Edison, NJ, and NattoPharma
R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or
www.menaq7.com.

For more information, please contact:

Kate Quackenbush, NattoPharma Director of Communications

P: 609-643-0749 x 220; E: kate.quackenbush@nattopharma.c

http://www.netfonds.no/quotes/release.php?id=20190226.OBI.20190226S36

[holmes]

Flott når noen kjøper 2 aksjer en halv krone opp så blir holmes 50 000 papirkroner rikere

[Christian]

Har du natto aksjer for over millionen?

[holmes]

Har akkurat 100 000 aksjer

[nofun]

Så du har økt med 10k ?

[holmes]

Det siste ble kjøpt i desember 2017, det var vel 10 000 ja. Har ikke gjort noe på lenge

[Christian]

Har du lyst til å komme med et regnestykke som estimerer resultat for 2019 @Holmes? Tipper du har regnet på det selv.

Også hvis noen gadd å forklare hvordan earnings er positive, men ebit negativ.

[holmes]

Det er en kombinasjon av renteinntekter og noe valutagevinst.

Her fra H2:

Net financial items in the period was positive NOK 2,3 million. NOK 1,4 million was interest income on the loan to Kaydence Pharma AS, NOK 1,1 million in net currency gain and NOK 0,3 million in interest expense and other financial expenses.

Når det kommer til skatt så har de en ikke-regnskapsført utsatt skattefordel med verdi på 45,3 millioner kroner.

Kan se på estimatene når jeg kommer hjem. Har det ikke her

[holmes]

Har du lyst til å komme med et regnestykke som estimerer resultat for 2019

Jeg er jo en langsiktig investor her så jeg ser ikke veldig nøye på enkeltår, men det er trenden over flere år som jeg først og fremst er i interessert i, og da er vi ved et spesielt spennende veiskille siden det ser ut som om vi går fra en situasjon der vi riktignok de siste årene har fått vekst i omsetning og redusering av underskuddet, men først nå går vi over til økende overskudd og det er jo tross alt en god del mer spennende siden det gir cash inn til selskapet. Når det er sagt så er det svært vanskelig å regne seg frem til bunnlinjen eksakt siden vi vet ganske lite om kostnadsveksten, bortsett fra at den skal være lavere enn omsetningsveksten. Har en skjematisk oversikt i excel, men kommer sikkert til å justere når jeg ser hva Nordea har regnet seg frem til.

[holmes]

Har også denne som viser omsetning /varesalg målt mot noen peers, der Nattopharma er det eneste lønnsomme selskapet.

Selskap	Resultat FY18 (mnok)	Market cap (mnok)
Photocure	-36.7	843
Hofseth Biocare	-84.7	778
NattoPharma	1.8	227
Biotec Pharmacon	-13.8	208

[Oxion]

Holmes. Det gleder meg at seriøse og dyktige skribenter, kommenterer Nattopharma.
En aksje som i mange år har vært glemt, og som nå snart virkelig vil komme frem i lyset.
Produktet er utrolig bra, flere titalls mill mennesker i verden trenger dette, og sannsynligvis vil vi se en explosiv vekst!!
Kaydence er en joker!!
Kan bli et bra Utbytteselskap…